MedTrace Logo

Osteoprotegerin (OPG) in Induced Chronic Obstructive Pulmonary Disease (COPD) Sputum

NCT00655954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2019-07-10

No results posted yet for this study

Summary

Evaluation of OPG level as disease markers has also been reported. It has been showed that patients with coronary artery disease had higher serum OPG levels than healthy volunteers. Moreover, serum OPG levels correlate with the number of stenotic coronary arteries

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

PROCEDURE

Induced sputum

Used Ultrasonic nebuliser

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sergei A Kharitonov, MD PhD · National Heart and Lung Institute

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655954 on ClinicalTrials.gov